CALLIDITAS THERAPEUTICS AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106 SEK | +1.87% |
|
+5.37% | -16.68% |
Presentation Operator MessageOperator (Operator)Welcome to the Calliditas Therapeutics Q4 repo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Sector
Pharmaceuticals
Calendar
2024-04-28
- LSX World Congress
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
104.1
SEK
Average target price
208
SEK
Spread / Average Target
+99.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.68% | 512M | |
| +3.82% | 69.91B | |
| +10.97% | 9.03B | |
| -17.03% | 4.75B | |
| +37.51% | 4.31B | |
| +3.92% | 3.88B | |
| +16.54% | 2.37B | |
| -24.13% | 2.26B | |
| -29.70% | 2.2B | |
| +9.09% | 1.98B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Transcript : Calliditas Therapeutics AB, Q4 2022 Earnings Call, Feb 23, 2023
